Kevin H Eng

List of Publications by Year
in descending order

55 papers	1,991 citations	304743 22 h-index	276875 41 g-index
57 all docs	57 docs citations	57 times ranked	4567 citing authors

#	Article	IF	Citations
1	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
2	Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. Journal of Allergy and Clinical Immunology, 2018, 141, 1028-1035.	2.9	172
3	Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Clinical Cancer Research, 2020, 26, 71-81.	7.0	109
4	Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight, 2019, 4, .	5.0	93
5	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clinical Cancer Research, 2017, 23, 7072-7083.	7.0	87
6	Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E672-81.	7.1	72
7	PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget, 2016, 7, 45352-45369.	1.8	72
8	On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve. Oncotarget, 2015, 6, 36308-36318.	1.8	71
9	Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-Î± and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecologic Oncology, 2015, 138, 352-357.	1.4	70
10	Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e104099.	2.5	65
11	Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. British Journal of Cancer, 2019, 120, 207-217.	6.4	62
12	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecologic Oncology, 2017, 145, 420-425.	1.4	61
13	Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecologic Oncology, 2017, 146, 491-497.	1.4	53
14	Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. Genome Research, 2020, 30, 347-360.	5.5	47
15	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	6.4	39
16	Statistical Tests for Clonality. Biometrics, 2007, 63, 522-530.	1.4	31
17	Lifetime exposure to ambient air pollution and methylation of tumor suppressor genes in breast tumors. Environmental Research, 2018, 161, 418-424.	7.5	31
18	USP1 Regulates TAZ Protein Stability Through Ubiquitin Modifications in Breast Cancer. Cancers, 2020, 12, 3090.	3.7	30

#	Article	IF	Citations
19	Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer. Cancer Immunology Research, 2021, 9, 790-810.	3.4	29
20	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes and Control, 2017, 28, 469-486.	1.8	28
21	Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. Gynecologic Oncology, 2015, 139, 228-235.	1.4	26
22	Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils. Cancer Immunology Research, 2020, 8, 819-828.	3.4	25
23	Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. OncoImmunology, 2017, 6, e1264563.	4.6	23
24	Differential Requirement for Src Family Tyrosine Kinases in the Initiation, Progression, and Metastasis of Prostate Cancer. Molecular Cancer Research, 2014, 12, 1470-1479.	3.4	22
25	TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. Gynecologic Oncology, 2015, 138, 159-164.	1.4	21
26	Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. Oncotarget, 2015, 6, 18641-18652.	1.8	20
27	Transient Genotype-by-Environment Interactions Following Environmental Shock Provide a Source of Expression Variation for Essential Genes. Genetics, 2010, 184, 587-593.	2.9	18
28	DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study. Epigenetics, 2016, 11, 643-652.	2.7	17
29	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, 2017, 117, 1063-1069.	6.4	16
30	Lifetime physical inactivity is associated with lung cancer risk and mortality. Cancer Treatment and Research Communications, 2018, 14, 37-45.	1.7	15
31	Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genetics, 2018, 14, e1007194.	3.5	15
32	In situ thermal ablation augments antitumor efficacy of adoptive T cell therapy. International Journal of Hyperthermia, 2019, 36, 22-36.	2.5	14
33	Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. Oncotarget, 2020, 11, 2669-2683.	1.8	14
34	A Phylogenetic Mixture Model for the Evolution of Gene Expression. Molecular Biology and Evolution, 2009, 26, 2363-2372.	8.9	13
35	Estrogen Receptor-Beta2 (ERÎ²2)â€“Mutant p53â€“FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC). Cancers, 2022, 14, 1120.	3.7	13
36	Randomized reverse marker strategy design for prospective biomarker validation. Statistics in Medicine, 2014, 33, 3089-3099.	1.6	12

#	Article	IF	Citations
37	Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. Gynecologic Oncology, 2017, 146, 52-57.	1.4	12
38	Wholeâ€exome sequencing of ovarian cancer families uncovers putative predisposition genes. International Journal of Cancer, 2020, 146, 2147-2155.	5.1	12
39	Src controls castration recurrence of <scp>CWR</scp>22 prostate cancer xenografts. Cancer Medicine, 2013, 2, 784-792.	2.8	11
40	Active and secondhand smoke exposure throughout life and DNA methylation in breast tumors. Cancer Causes and Control, 2019, 30, 53-62.	1.8	10
41	Differential Antigen Expression Profile Predicts Immunoreactive Subset of Advanced Ovarian Cancers. PLoS ONE, 2014, 9, e111586.	2.5	10
42	Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer. PLoS ONE, 2018, 13, e0206913.	2.5	9
43	Evaluation of satisfaction with workâ€"life balance among U.S. Gynecologic Oncology fellows: A cross-sectional study. Gynecologic Oncology Reports, 2016, 16, 17-20.	0.6	8
44	HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecologic Oncology, 2016, 142, 158-162.	1.4	8
45	Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells. Leukemia, 2020, 34, 2460-2472.	7.2	7
46	Finding Jumps in Otherwise Smooth Curves: Identifying Critical Events in Political Processes. Political Analysis, 2010, 18, 57-77.	3.3	5
47	Connecting Prognostic Ligand Receptor Signaling Loops in Advanced Ovarian Cancer. PLoS ONE, 2014, 9, e107193.	2.5	5
48	Transmission of X-linked Ovarian Cancer: Characterization and Implications. Diagnostics, 2020, 10, 90.	2.6	5
49	Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. Communications Biology, 2021, 4, 862.	4.4	5
50	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
51	Transcriptional changes associated with growth of muscle-invasive bladder cancer cell lines in nude mice. American Journal of Clinical and Experimental Urology, 2018, 6, 138-148.	0.4	5
52	VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients. Cancer Immunology, Immunotherapy, 2022, 71, 2355-2369.	4.2	5
53	Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer. Genes and Cancer, 2015, 6, 399-407.	1.9	4
54	Loss of MAGEC3 Expression Is Associated with Prognosis in Advanced Ovarian Cancers. Cancers, 2022, 14, 731.	3.7	2

#	Article	IF	Citations
55	Patient derived models of bladder cancer enrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor cell compartment.. American Journal of Clinical and Experimental Urology, 2021, 9, 416-434.	0.4	0